文献速递临床免疫质量管理与危急值临床生化

mSTOP机器学习纵向预测模型临床验证与实施:早期识别无获益于免疫检查点抑制剂治疗的非小细胞肺癌患者

Clinical validation and implementation of mSTOP, a machine learning-based, longitudinal prediction model for the early identification of non-small cell lung cancer patients who not benefit from immune checkpoint inhibitor treatment.
PubMed 文献 · Clin Chem Lab Med · 2026-04-29

本研究对基于CEA和Cyfra 21-1的mSTOP机器学习纵向预测模型进行临床验证,用于识别对免疫检查点抑制剂无响应的转移性非小细胞肺癌患者。双中心242例患者验证显示mSTOP识别35.1%无响应患者,阳性预测值84.8%,联合CT影像阳性预测值升至95.7%。模型可减少过度治疗并节省费用,研究还设计了ICT系统实现实时计算与质控。

要点

  • mSTOP基于CEA和Cyfra 21-1纵向数据,识别35.1%免疫治疗无响应患者,阳性预测值84.8%。
  • mSTOP联合CT影像阳性预测值达95.7%,识别19.8%无响应患者。
  • 模型预计避免6.7%至17.4%过度治疗,每例患者节省569至5306欧元。

核心结论

  • mSTOP模型诊断准确性及临床经济影响支持开发ICT系统实现自动化实时临床应用。

研究设计与样本

  • 诊断准确性基于双中心242例转移性非小细胞肺癌患者验证队列。
  • 临床与财务影响采用离散事件模拟模型评估,输出参数为治疗不足、过度治疗和财务影响。
  • 设计ICT系统及多参数质控策略以支持mSTOP实时运行与质量控制。

主要发现

  • mSTOP识别35.1%无响应患者,阳性预测值84.8%,与CT影像相当。
  • mSTOP联合CT影像阳性预测值增至95.7%,识别19.8%无响应患者。
  • 预计避免过度治疗范围6.7%至17.4%,每例患者节省569至5306欧元,取决于所用临床场景。
  • ICT系统将mSTOP算法整合至实验室与医疗信息系统,支持连续实时计算。

关键数值与推荐

  • mSTOP基于CEA和Cyfra 21-1,因NSE分析前挑战大而选为最佳替代模型。
  • 双中心验证队列242例转移性非小细胞肺癌患者。
  • mSTOP阳性预测值84.8%,联合CT影像阳性预测值95.7%。
  • 避免过度治疗6.7%至17.4%,每例患者节省569至5306欧元。

临床怎么用

  • mSTOP可实时计算,辅助识别可能无获益于免疫检查点抑制剂治疗的NSCLC患者。
  • 联合CT影像可提高阳性预测值至95.7%,支持临床决策。
  • ICT系统与多参数质控策略保障模型自动化运行与质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: There has been a lot of interest in the field of laboratory medicine regarding the use of machine learning (ML)-based prediction models. The longitudinal ML-based Serum Tumor marker-based Outcome Prediction (STOP) model was previously developed to identify non-small cell lung cancer (NSCLC) patients who do not respond to immune checkpoint inhibitor treatment. Due to significant preanalytical challenges with the NSE tumor marker, the best-performing alternative model, mSTOP model based on CEA and Cyfra 21-1, was selected for validation of its diagnostic accuracy, clinical- and financial impact. METHODS: Diagnostic accuracy was based on a dual-center validation cohort of 242 metastatic NSCLC patients. The clinical and financial impact of mSTOP was investigated using a previously described Discrete Event Simulation (DES) model with under-treatment, overtreatment, and financial impact as output parameters. Finally, an ICT system and a multi-parametric QC strategy were designed to enable real-time operation and quality control of mSTOP. RESULTS: mSTOP identified 35.1 % of nonresponding patients, with a positive predictive value (PPV) of 84.8 %, which was comparable to CT-imaging. In combination with CT- imaging, the PPV increased to 95.7 %, identifying 19.8 % of non-responding patients. Estimated avoided overtreatment ranged from 6.7 % to 17.4 %, reflecting a financial savings of €569 to €5306 per patient, depending on the clinical mSTOP scenario used. The developed ICT system incorporated the mSTOP algorithm within the laboratory and healthcare information system. It allowed for continuous real-time mSTOP calculations. CONCLUSIONS: The obtained diagnostic mSTOP characteristics and their corresponding clinical and financial characteristics prompted the development of an ICT system that supports automated, real-time, clinical application.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. van Rossum HH, van der Schaar M, Buma AIG, et al. Clinical validation and implementation of mSTOP, a machine learning-based, longitudinal prediction model for the early identification of non-small cell lung cancer patients who not benefit from immune checkpoint inhibitor treatment. Clin Chem Lab Med. 2026. PMID: 42054314. doi:10.1515/cclm-2025-1624

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。